R

Rigel Pharmaceuticals
D

RIGL

16.190
USD
-0.80
(-4.71%)
Post Trading
Volume
6,557
EPS
1
Div Yield
-
P/E
16
Market Cap
289,201,290
Related Instruments
ALNY
ALNY
-17.550
(-7.29%)
223.260 USD
AMGN
AMGN
-15.98
(-5.39%)
280.48 USD
BIIB
BIIB
-10.320
(-8.30%)
114.050 USD
BMY
BMY
-1.830
(-3.33%)
53.130 USD
GILD
GILD
-5.250
(-4.84%)
103.180 USD
INCY
INCY
-4.080
(-6.67%)
57.060 USD
REGN
REGN
-21.47
(-3.71%)
557.85 USD
VRTX
VRTX
-4.03
(-0.85%)
472.75 USD
More
News

Title: Rigel Pharmaceuticals Inc

Sector: Healthcare
Industry: Biotechnology
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.